| abstract |
Compositions, methods, and combination therapies for the treatment of lymphomas, leukemias, melanomas, prostate cancer, and metastatic disease are provided. Specifically, compositions comprising anti-α4 integrin immunoglobulins or immunoglobulins that bind to an α4 integrin ligand (e.g., MadCAM-1 and VCAM-1) are disclosed for use in inhibiting tumor growth and progression and inhibition of metastases. A preferred immunoglobulin for use in treating tumors and metastases is natalizumab. The compositions and methods using these immunoglobulins can be used alone or in combination with other reagents and cancer treatment modalities. |